1. Home
  2. GBIO vs GSIW Comparison

GBIO vs GSIW Comparison

Compare GBIO & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.11

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

GSIW

Garden Stage Limited

HOLD

Current Price

$0.15

Market Cap

33.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBIO
GSIW
Founded
2016
2016
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.4M
33.9M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
GBIO
GSIW
Price
$5.11
$0.15
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$10.67
N/A
AVG Volume (30 Days)
75.9K
1.4M
Earning Date
11-05-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,270,000.00
$5,368,221.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
283.23
52 Week Low
$3.00
$0.09
52 Week High
$15.30
$1.79

Technical Indicators

Market Signals
Indicator
GBIO
GSIW
Relative Strength Index (RSI) 40.76 47.18
Support Level $5.14 $0.14
Resistance Level $5.38 $0.16
Average True Range (ATR) 0.26 0.01
MACD 0.01 0.00
Stochastic Oscillator 18.36 41.13

Price Performance

Historical Comparison
GBIO
GSIW

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

Share on Social Networks: